Alzheimer's disease (AD) is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. AD is a progressive brain disorder that leads to neurodegeneration, cognitive deficits, and memory decline. Aside from cognitive impairments, approximately 50% of AD patients experience some degree of depression or anxiety, and this number is expected to rise due to the covid-19 lockdown and restrictions. While some consider these affective symptoms as non-cognitive symptoms of AD, related to the AD pathology; others suspect that the affective symptoms are actually risk factors that precede AD pathology.
Finding a biomarker for AD is critical for treating and managing the disease. Anxiety and depression may be relevant factors for such biomarkers. Furthermore, in order to develop better clinical interventions to help with AD-related affective symptoms, we first must understand the relationship and shared molecular mechanisms (if there are any) between the cognitive and affective symptoms of AD. The first aim of this Research Topic is to elucidate the underlying mechanisms of AD-related affective symptoms. The second aim is to explore the effect of stress on the development of AD-related cognitive symptoms.
This Research Topic aims to collect original research articles and high-quality reviews that focus on the common underlying mechanisms of anxiety, depression, and cognitive decline in AD, as well as possible treatments. This Research Topic will mainly focus on pre-clinical research in various animal models, but relevant clinical studies are also welcome. Opinion articles will not be accepted.
This Research Topic covers themes such as:
1. Affective symptoms as risk factor to AD - Time course, progression and biomarkers of anxiety and depression in AD
2. Effect of exposure to chronic and acute stress on the progression of AD-related cognitive symptoms
2. Molecular and cellular mechanisms of anxiety or depression in AD
3. Crosstalk between affective disorder and cognitive deficits in AD
4. Therapeutic strategies and clinical interventions, focusing on treating AD-related affective disorders.
Alzheimer's disease (AD) is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. AD is a progressive brain disorder that leads to neurodegeneration, cognitive deficits, and memory decline. Aside from cognitive impairments, approximately 50% of AD patients experience some degree of depression or anxiety, and this number is expected to rise due to the covid-19 lockdown and restrictions. While some consider these affective symptoms as non-cognitive symptoms of AD, related to the AD pathology; others suspect that the affective symptoms are actually risk factors that precede AD pathology.
Finding a biomarker for AD is critical for treating and managing the disease. Anxiety and depression may be relevant factors for such biomarkers. Furthermore, in order to develop better clinical interventions to help with AD-related affective symptoms, we first must understand the relationship and shared molecular mechanisms (if there are any) between the cognitive and affective symptoms of AD. The first aim of this Research Topic is to elucidate the underlying mechanisms of AD-related affective symptoms. The second aim is to explore the effect of stress on the development of AD-related cognitive symptoms.
This Research Topic aims to collect original research articles and high-quality reviews that focus on the common underlying mechanisms of anxiety, depression, and cognitive decline in AD, as well as possible treatments. This Research Topic will mainly focus on pre-clinical research in various animal models, but relevant clinical studies are also welcome. Opinion articles will not be accepted.
This Research Topic covers themes such as:
1. Affective symptoms as risk factor to AD - Time course, progression and biomarkers of anxiety and depression in AD
2. Effect of exposure to chronic and acute stress on the progression of AD-related cognitive symptoms
2. Molecular and cellular mechanisms of anxiety or depression in AD
3. Crosstalk between affective disorder and cognitive deficits in AD
4. Therapeutic strategies and clinical interventions, focusing on treating AD-related affective disorders.
